San Francisco–based Ossium Health has carried out three transplants for cancer patients using stem cells from deceased donors ...

A GENETIC variant, the BIM deletion polymorphism (BDP), has been identified by researchers to significantly enhance leukemia ...

Syndax Pharmaceuticals advances Revumenib for relapsed AML with FDA decision pending. See why SNDX stock is a key player in ...

Syndax Pharmaceuticals (NASDAQ:SNDX) fell ~23% in the premarket on Tuesday after the cancer drug developer reported topline ...

Although Bruton tyrosine kinase (BTK) inhibitor monotherapy in chronic lymphocytic leukemia (CLL) has been a game-changer, ...

Oct. 9, 2024 — Researchers have created a CRISPR-based rapid molecular diagnostic for two forms of leukemia that are driven by mutations that involve gene fusions. The technology accurately ...

Syndax (SNDX) announced that multiple abstracts evaluating revumenib, an oral small molecule menin inhibitor, have been accepted for oral ...

Aucatzyl is a CAR T-cell therapy that targets CD19 and has been designed to minimize excessive activation of the programmed T ...

The FDA approved obecabtagene autoleucel for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia.

Officials claim a Alicia Campbell, of Mays Landing, claimed her child needed special treatment at a leukemia center in Texas ...

Obe-cel in r/r adult B-ALL – The FELIX Study and regulatory updates Obe-cel is under regulatory review in both the EU and the UK ... Post period, Autolus presented data at the 2024 Lymphoma, Leukemia ...